2.46
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Boundless Bio
From its filings with the US Securities and Exchange Commission
Boundless Bio is based in La Jolla, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BOLD. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $58.2m. At that date it held total assets of $157.1m and shareholders' equity of $98.7m.
We are a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14 to 17% of cancer patients. Our mission is to be the foremost biopharma company interrogating ecDNA biology to deliver transformative therapies that improve and extend the lives of patients with previously intractable oncogene amplified cancers.
Spyglass is our proprietary platform that leverages ecDNA biology to identify new cancer drug targets. These targets span multiple, diverse synthetic lethal nodes in oncogene amplified cancers. In addition to the ecDTx programs described above, we have preclinically validated multiple additional targets and conducted ecDTx drug discovery efforts to identify candidates against certain targets.
We consider ourselves to be the world’s leading ecDNA company. To our knowledge, we are the first company developing new cancer medicines directed at amplification biology and ecDNA function and the only company to date to bring an ecDTx into the clinic. All of our ecDTx have been discovered internally, and we retain global rights for all of our programs. Our efforts build on the work of our scientific founders and advisors, including Dr.
Quoted from its 10-K, filed 9 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 28 Mar 2024
- Employees
- 71
- Website
- boundlessbio.com ↗
- Head office
- 11099 NORTH TORREY PINES ROAD, LA JOLLA, CA, 92037
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Leadership
Pay as last reported
- Dr. Jonathan LimIndependent Chairman of the Board$411,927
- Mr. Zachary HornbyPresident, Chief Executive Officer, Director, since 2019$6.1m
- Mr. David HinkleSenior Vice President - Finance, Controller and Corporate Treasurer
- Dr. Christian HassigChief Scientific Officer$2.2m
- Dr. Robert DoebeleChief Medical Officer
- Ms. Jessica OienChief Legal Officer and Corporate Secretary
- Dr. Christine BrennanIndependent Director$369,844
- Ms. Kristina BurowIndependent Director$364,969
- Dr. James ChristensenIndependent Director$358,712
- Ms. Jennifer LewIndependent Director$369,962
- Dr. Nancy WhitingIndependent Director$357,962
- Ms. Renee LeckInvestors, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Boundless Bio Inc employs 71 full-time employees in San Diego, California.
- Boundless Bio Inc's Spyglass platform identifies ecDNA targets for cancer therapeutics.
- BBI-355 is an oral CHK1 inhibitor showing tumor regressions in preclinical models.
Weaknesses
- Boundless Bio Inc's IPO occurred on March 28, 2024, with limited market history.
- Boundless Bio Inc has only two ecDTx candidates in development.
- Boundless Bio Inc's clinical trials are in Phase I/II stages with limited patient data.
Opportunities
- Boundless Bio Inc's ecDNA-directed therapeutics target unmet needs in oncogene amplified cancers.
- Boundless Bio Inc's BBI-355 is in a first-in-human Phase I/II trial for oncogene amplified cancers.
- Boundless Bio Inc's second ecDTx BBI-825 targets ribonucleotide reductase for ecDNA assembly.
Threats
- Boundless Bio Inc faces competition in the oncology sector with multiple cancer therapeutics in development.
- Boundless Bio Inc's clinical trials may encounter delays in patient recruitment for oncogene amplified cancers.
- Boundless Bio Inc's ecDNA-targeting approach could face regulatory challenges in drug approval processes.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.